Pipeline

Diabetes is a disease characterized by abnormally high levels of blood glucose and inadequate levels of insulin. Glucose is a simple sugar used by all the cells of the body to produce energy and support life.

Humans need a minimum level of glucose in their blood at all times to function and stay alive. Insulin is a peptide hormone naturally secreted by the pancreas to regulate the body's management of glucose.

When a healthy individual begins a meal, the pancreas releases a natural spike of insulin, called the first-phase insulin release, which is critical to the body's overall control of glucose.

Many patients with diabetes lack the first-phase insulin release and must treat themselves with daily meal-time insulin injections to avoid the negative effects of hyperglycemia and hypoglycemia.

BIOD-Glucose-responsive Basal

BIOD-Glucose-responsive Basal is a new chemical entity in preclinical development as a treatment for diabetes. It is called "glucose-reponsive" basal because it releases insulin proportionally to subcutaneous glucose concentration and, as a result, automatically adjusts to unanticipated changes in patients' insulin needs, such as exercise or fever, to maintain a more normal glycemic range.

Patients with Type 2 diabetes who are currently treated with basal insulin doses titrated to achieve target fasting-glucose readings may be "stuck" with that basal dose for the remainder of the day even though that dose may not be optimal for changing conditions that affect their glucose levels. BIOD-Glucose-responsive Basal is being developed to address this problem and prevent the hypoglycemia, hyperglycemia and weight gain often associated with current basal insulins.

Smart Insulin....in vivo proof of Concept